Business context and reporting period
Filing identity: The supplied filing is Neoleukin Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2020 (filed November 9, 2020), not a filing for Neurogene Inc. The company develops de novo protein immunotherapies; its lead candidate, NL-201, remained preclinical.
Financial results and liquidity
| Metric | Three months ended September 30, 2020 | Three months ended September 30, 2019 | Nine months ended September 30, 2020 | Nine months ended September 30, 2019 |
|---|---|---|---|---|
| Revenue | No product revenue; the filing says the company has not generated product-sales revenue. | |||
| Research and development expense | $6.2 million | $1.4 million | $16.6 million | $(0.5) million |
| General and administrative expense | $3.9 million | $10.4 million | $12.4 million | $15.4 million |
| Net loss | $2.2 million | $59.1 million | $20.6 million | $61.3 million |
| Net loss per share, basic and diluted | $0.04 | $2.26 | $0.41 | $2.51 |
Amounts are U.S. dollars; expenses and losses are shown as reported, with parentheses denoting negative amounts. No meaningful revenue margin is reported because the company had no product revenue.
- Cash and cash equivalents: $201.2 million at September 30, 2020, versus $143.1 million at December 31, 2019. Including restricted cash, the cash-flow statement reports $202.0 million.
- Cash flows, nine months: $15.3 million used in operations, $1.6 million used in investing, and $75.8 million provided by financing; cash, cash equivalents and restricted cash increased by $58.9 million.
- Liquidity: Working capital was $196.7 million. Management expected cash on hand to fund planned operations into 2023, subject to the risks and assumptions described in the filing.
- Debt and obligations: The balance sheet reports no conventional borrowings. Lease liabilities totaled $11.8 million, principally operating leases, including $11.4 million non-current.
- Equity financing: The July 2020 public offering generated $71.3 million net proceeds from common stock and pre-funded warrants.
Material changes versus comparable periods
- Quarterly net loss fell substantially from 2019, largely because the 2019 period included $47.7 million of acquired in-process R&D expense related to the merger; 2020 also included a $7.8 million gain on the sale of Aquinox Canada.
- R&D spending increased as NL-201 IND-enabling work and other Neoleukin programs advanced. The 2019 nine-month R&D figure was a credit, reflecting reductions in accrued costs after vendor confirmations.
- Operating cash use increased to $15.3 million from $10.8 million for the first nine months, reflecting higher development spending, partly offset by cash received from the Canadian subsidiary sale.
- Cash increased following the July financing. Common shares outstanding were 41.9 million at September 30; the filing also reports 12.7 million pre-funded warrants, which are included in loss-per-share calculations.
Outlook, commentary and risks
- Management targeted submission of an IND application for NL-201 in the fourth quarter of 2020 and reported submitting a Clinical Trial Notification application in Australia. It said COVID-19 was not then expected to delay the IND, while acknowledging possible impact.
- NL-201 had completed GLP toxicology in-life dosing with no unexpected toxicities reported; the company had not yet tested any candidate in clinical trials. Development, safety, regulatory, manufacturing and financing outcomes remained uncertain.
- The company sold Aquinox Canada on July 31, 2020, for $8.2 million cash consideration and recognized a $7.8 million net gain after transaction costs. The sale did not qualify as discontinued operations.
- In November 2020, after quarter-end, the company amended its Seattle headquarters lease to extend the rent commencement date to February 1, 2021 and the base-term expiration to February 1, 2029; the filing says the amendment did not affect September 30 lease balances.
- COVID-19 could disrupt research, supply, regulatory work and future trials. Other central risks include the early stage and unproven nature of the platform, dependence on NL-201, reliance on third-party manufacturers and study providers, competition, intellectual-property protection, and the need for additional capital over time.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Neoleukin Therapeutics, Inc. (ticker NLTX), whereas the request metadata names Neurogene Inc.
- Check subsequent filings for whether the NL-201 IND was submitted on schedule and for any regulatory response or clinical-trial start.
- Review cash burn, financing needs and whether management’s “into 2023” liquidity estimate remained valid as development spending evolved.
- Assess the impact of pre-funded warrants, options and other potential share issuance on dilution and per-share results.
- Verify the continuing effect of the Aquinox Canada sale, Seattle facility spending and lease commitments, and any COVID-19-related delays.